Sep 2025 (Q2 FY26) — Nov 12, 2025
ORIX Q2 FY26 — Strong H1 Performance Drives Upgraded Outlook and Increased Shareholder Returns
Read the full callORIX earnings: last reported Wed, 12 Nov 2025, for the quarter ended Sep 2025.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 776,501 | +15.6% YoY | Quarterly, as filed | Quarter to Mar 2024 | Revenue from operations as filed. |
| Operating margin | 12.9 | +1.5 pts YoY | Operating profit / revenue | Quarter to Mar 2024 | For the quarter; a change is in percentage points. |
| Net profit | 126,927 | +105.8% YoY | Quarterly, as filed | Quarter to Mar 2024 | Profit after tax as filed. |
Price
1Y: $24.94 on 17 Oct 2025 → $36.52. High $41.31 (5 Aug 2026), low $24.22 (30 Oct 2025).
Overview
Call summaries
ORIX Q2 FY26 — Strong H1 Performance Drives Upgraded Outlook and Increased Shareholder Returns
Read the full callORIX Q1 FY26 — Strong Q1 Net Income and Capital Recycling Gains
Read the full callEvery analysed call
Financials
Net profit, year on year: +106% (quarter to mar 2024 against mar 2023).
| Line item | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Sales | 626,579 | 652,252 | 707,003 | 630,028 | 671,529 | 682,761 | 678,125 | 776,501 |
| Expenses | 553,377 | 632,288 | 639,934 | 541,078 | 594,849 | 601,978 | 581,962 | 675,986 |
| Operating profit | 73,202 | 19,964 | 67,069 | 88,950 | 76,680 | 80,783 | 96,163 | 100,515 |
| Operating margin | 11.7% | 3.1% | 9.5% | 14.1% | 11.4% | 11.8% | 14.2% | 12.9% |
| Interest | 17,026 | 17,774 | 29,575 | 37,158 | 38,987 | 47,810 | 47,703 | 49,734 |
| Profit before tax | 95,900 | 188,187 | 80,560 | 119,902 | 83,695 | 95,075 | 125,540 | 159,968 |
| Tax rate | 34.3% | 45.9% | 23.3% | 24.1% | 24.7% | 30.1% | 30.7% | 24.4% |
| Net profit | 64,659 | 100,794 | 60,386 | 89,610 | 61,687 | 65,134 | 91,105 | 126,927 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1,997 | 2,036 | 1,997 | 1,815 | 1,661 | 1,462 | 1,479 | 1,386 |
| Reserves | 23,077 | 25,369 | 24,784 | 23,885 | 22,939 | 21,547 | 22,444 | 21,961 |
| Total liabilities | 83,184 | 92,020 | 94,453 | 89,483 | 87,673 | 81,286 | 84,903 | 83,886 |
| Total assets | 109,940 | 120,352 | 122,475 | 117,244 | 114,823 | 107,889 | 112,835 | 112,877 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 5,307 | 9,601 | 9,955 | 9,059 | 6,857 | 8,219 | 8,698 | 8,587 |
| Cash from investing | -7,892 | -13,543 | -10,926 | -6,641 | -8,250 | -9,074 | -8,762 | -6,989 |
| Cash from financing | 1,505 | 2,659 | 360 | -2,517 | 3,292 | -565 | 999 | -1,007 |
| Net cash flow | -1,097 | -1,366 | -503 | 100 | 2,066 | -1,200 | 914 | 810 |
| Capital expenditure | -562 | -410 | -397 | -364 | -778 | -507 | -462 | -471 |
| Free cash flow | 4,745 | 9,192 | 9,558 | 8,695 | 6,079 | 7,712 | 8,236 | 8,116 |
3 filings, all on May 20, 2026.
Purchases
$905
3 purchases by 3 insiders
Sales
None
No insider sold shares.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Otsuka Takashi | $503 | — | May 20, 2026 |
| Matsuzaki Satoru | $251 | — | May 20, 2026 |
| Ishihara Tomohiko | $151 | — | May 20, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | Ishihara Tomohiko Executive Officer | Purchase | 4 | $151 |
| May 20, 2026 | Matsuzaki Satoru See remarks | Purchase | 7 | $251 |
| May 20, 2026 | Otsuka Takashi See Remarks | Purchase | 13 | $503 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow ORIX CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading